This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Philip D. Gregory net worth and biography

Philip Gregory Biography and Net Worth

Insider of 2seventy bio

Philip D. Gregory, D.Phil., is chief scientific officer at 2seventy bio. Previously, Philip served as chief scientific officer at bluebird bio for over six years. Philip was formerly with Sangamo BioSciences, where he held multiple leadership positions over a nearly 15-year tenure, most recently serving as chief scientific officer and senior vice president, research. In this role, he was responsible for the scientific direction and strategic research planning for the company. Philip played an integral role in Sangamo’s partnerships and drove early discovery and development for several IND candidates in multiple therapeutic areas. Prior to joining Sangamo, he was a postdoctoral fellow at Ludwig-Maximilians-Universität München. Philip holds a D.Phil in biochemistry from Oxford University, Keble College and a B.Sc. in microbiology from Sheffield University.

What is Philip D. Gregory's net worth?: The estimated net worth of Philip D. Gregory is at least $738,694.40 as of January 5th, 2024. Dr. Gregory owns 230,842 shares of 2seventy bio stock worth more than $738,694 as of December 18th. This net worth estimate does not reflect any other investments that Dr. Gregory may own. Learn More about Philip D. Gregory's net worth.
How do I contact Philip D. Gregory?: The corporate mailing address for Dr. Gregory and other 2seventy bio executives is , , . 2seventy bio can also be reached via phone at 339-499-9300 and via email at [email protected]. Learn More on Philip D. Gregory's contact information.
Has Philip D. Gregory been buying or selling shares of 2seventy bio?: Philip D. Gregory has not been actively trading shares of 2seventy bio during the last quarter. Most recently, Philip D. Gregory sold 795 shares of the business's stock in a transaction on Friday, January 5th. The shares were sold at an average price of $3.75, for a transaction totalling $2,981.25. Following the completion of the sale, the insider now directly owns 230,842 shares of the company's stock, valued at $865,657.50. Learn More on Philip D. Gregory's trading history.
Who are 2seventy bio's active insiders?: 2seventy bio's insider roster includes William Baird, III (CFO), Philip Gregory (Insider), Nicola Heffron (COO), and Nick Leschly (CEO). Learn More on 2seventy bio's active insiders.
Are insiders buying or selling shares of 2seventy bio?: During the last twelve months, 2seventy bio insiders bought shares 2 times. They purchased a total of 630,000 shares worth more than $3,143,100.00. During the last twelve months, insiders at the sold shares 13 times. They sold a total of 151,152 shares worth more than $585,233.27. The most recent insider tranaction occured on December, 13th when insider Jessica Snow sold 2,287 shares worth more than $7,387.01. Insiders at 2seventy bio own 7.2% of the company. Learn More about insider trades at 2seventy bio.
Information on this page was last updated on 12/13/2024.

Philip D. Gregory Insider Trading History at 2seventy bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/5/2024	Sell	795	$3.75	$2,981.25	230,842
1/3/2024	Sell	25,613	$3.87	$99,122.31	231,637
8/22/2023	Sell	6,159	$5.49	$33,812.91	257,250
8/3/2023	Sell	3,966	$6.13	$24,311.58	263,409
1/11/2023	Sell	1,076	$10.63	$11,437.88	99,518
1/9/2023	Sell	3,794	$10.33	$39,192.02	100,594
8/5/2022	Sell	2,407	$16.23	$39,065.61	104,388
7/15/2022	Sell	2,365	$13.81	$32,660.65	106,795
1/7/2022	Sell	1,452	$23.91	$34,717.32

Philip D. Gregory Buying and Selling Activity at 2seventy bio

2seventy bio Company Overview

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.20

$3.20

50 Day Range

MA: $4.25

$3.11

$5.21

2 Week Range

Now: $3.20

$2.89

$6.40

Volume

105 shs

Average Volume

714,748 shs

Market Capitalization

$165.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad